Elevated expression of the EZH2 gene in CALR-mutated patients with primary myelofibrosis

Risk factors for infections in myelofibrosis: role of disease status and treatment. A multicenter study of 507 patients

(2016) Nicola Polverelli et al.   AMERICAN JOURNAL OF HEMATOLOGY

Primary myelofibrosis: 2017 update on diagnosis, risk-stratification, and management

(2016) Ayalew Tefferi   AMERICAN JOURNAL OF HEMATOLOGY

Mutant calreticulin-expressing cells induce monocyte hyperreactivity through a paracrine mechanism

(2016) Michael R. Garbati et al.   AMERICAN JOURNAL OF HEMATOLOGY

Activation of the thrombopoietin receptor by mutant calreticulin in CALR-mutant myeloproliferative neoplasms

(2016) M. Araki et al.   BLOOD

Improved Survival of Calreticulin-Mutated Patients Compared With Janus Kinase 2 in Primary Myelofibrosis: A Meta-Analysis

(2016) Hampig Raphael Kourie et al.   Clinical Lymphoma Myeloma & Leukemia

Allogeneic Transplantation for Patients With Advanced Myelofibrosis: Splenomegaly and High Serum LDH are Adverse Risk Factors for Successful Engraftment

(2016) Usama Gergis et al.   Clinical Lymphoma Myeloma & Leukemia

Multifaceted role of the polycomb-group gene EZH2 in hematological malignancies

(2016) Goro Sashida et al.   INTERNATIONAL JOURNAL OF HEMATOLOGY

Calreticulin-mutant proteins induce megakaryocytic signaling to transform hematopoietic cells and undergo accelerated degradation and Golgi-mediated secretion

(2016) Lijuan Han et al.   Journal of Hematology & Oncology

Role of the Polycomb Repressive Complex 2 (PRC2) in Transcriptional Regulation and Cancer

(2016) Anne Laugesen et al.   Cold Spring Harbor Perspectives in Medicine

Update from the latest WHO classification of MPNs: a users manual

(2016) F. Passamonti et al.   Hematology-American Society of Hematology Education Program

Atg3 Overexpression Enhances Bortezomib-Induced Cell Death in SKM-1 Cell

(2016) Lin Zhuang et al.   PLoS One

Rationale for revision and proposed changes of the WHO diagnostic criteria for polycythemia vera, essential thrombocythemia and primary myelofibrosis

(2015) T Barbui et al.   Blood Cancer Journal

Prolonged Ezh2 Depletion in Glioblastoma Causes a Robust Switch in Cell Fate Resulting in Tumor Progression

(2015) Nienke A. de Vries et al.   Cell Reports

Celastrol Induces Autophagy by Targeting AR/miR-101 in Prostate Cancer Cells

(2015) Jianquan Guo et al.   PLoS One

Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis

(2014) E. Rumi et al.   BLOOD

Integrated genomic analysis illustrates the central role of JAK-STAT pathway activation in myeloproliferative neoplasm pathogenesis

(2014) R. Rampal et al.   BLOOD

Distinct clinical characteristics of myeloproliferative neoplasms with calreticulin mutations

(2014) H. Andrikovics et al.   HAEMATOLOGICA

Uncovering the roles of miRNAs and their relationship with androgen receptor in prostate cancer

(2014) Song ChunJiao et al.   IUBMB LIFE

The mutation profile of JAK2 and CALR in Chinese Han patients with Philadelphia chromosome-negative myeloproliferative neoplasms

(2014) Zhiyuan Wu et al.   Journal of Hematology & Oncology

CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons

(2014) A Tefferi et al.   LEUKEMIA

Calreticulin mutation-specific immunostaining in myeloproliferative neoplasms: pathogenetic insight and diagnostic value

(2014) A M Vannucchi et al.   LEUKEMIA

Type 1 vs type 2 calreticulin mutations in primary myelofibrosis: differences in phenotype and prognostic impact

(2014) A Tefferi et al.   LEUKEMIA

Calreticulin gene mutations in myeloproliferative neoplasms without Janus kinase 2 mutations

(2014) Chao Sun et al.   LEUKEMIA & LYMPHOMA

Multiple mechanisms deregulate EZH2 and histone H3 lysine 27 epigenetic changes in myeloid malignancies

(2013) S N Khan et al.   LEUKEMIA

Somatic CALR Mutations in Myeloproliferative Neoplasms with Nonmutated JAK2

(2013) J. Nangalia et al.   NEW ENGLAND JOURNAL OF MEDICINE

Somatic Mutations of Calreticulin in Myeloproliferative Neoplasms

(2013) Thorsten Klampfl et al.   NEW ENGLAND JOURNAL OF MEDICINE

Identification of Novel AR-Targeted MicroRNAs Mediating Androgen Signalling through Critical Pathways to Regulate Cell Viability in Prostate Cancer

(2013) Wenjuan Mo et al.   PLoS One

The Dynamic International Prognostic Scoring System for myelofibrosis predicts outcomes after hematopoietic cell transplantation

(2012) B. L. Scott et al.   BLOOD

Calreticulin signaling in health and disease

(2012) Wen-An Wang et al.   INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY

A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis

(2012) Srdan Verstovsek et al.   NEW ENGLAND JOURNAL OF MEDICINE

JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis

(2012) Claire Harrison et al.   NEW ENGLAND JOURNAL OF MEDICINE

The critical roles of endoplasmic reticulum chaperones and unfolded protein response in tumorigenesis and anticancer therapies

(2012) B Luo et al.   ONCOGENE

Inactivation of polycomb repressive complex 2 components in myeloproliferative and myelodysplastic/myeloproliferative neoplasms

(2011) J. Score et al.   BLOOD

MicroRNAs as Regulators of Signal Transduction in Urological Tumors

(2011) A. Fendler et al.   CLINICAL CHEMISTRY

Structural and Functional Relationships between the Lectin and Arm Domains of Calreticulin

(2011) Cosmin L. Pocanschi et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

MicroRNA-101 negatively regulates Ezh2 and its expression is modulated by androgen receptor and HIF-1α/HIF-1β

(2010) Paul Cao et al.   Molecular Cancer

Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders

(2010) Thomas Ernst et al.   NATURE GENETICS

Calreticulin, a multi-process calcium-buffering chaperone of the endoplasmic reticulum

(2009) Marek Michalak et al.   BIOCHEMICAL JOURNAL

The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes

(2009) J. W. Vardiman et al.   BLOOD

Systemic Delivery of Synthetic MicroRNA-16 Inhibits the Growth of Metastatic Prostate Tumors via Downregulation of Multiple Cell-cycle Genes

(2009) Fumitaka Takeshita et al.   MOLECULAR THERAPY